drugset

drugset / Trial / NCT05856513

Pharmacokinetics of ZSP1273 in Participants With Hepatic Impairment

NCT05856513 ↗

Phase 1 Completed 24 enrolled Guangdong Raynovent Biotech Co., Ltd

Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of ZSP1273.

Timeline

Start: 2023-06-15
Primary completion: 2023-07-04
Completion: 2023-07-04

Publications

Li C, Li H, Mai J, Zhang H, Wu M, Ding Y, Huang J. Single-Dose Tolerability and Pharmacokinetics of Onradivir in Chinese Patients with Hepatic Impairment and Healthy Matched Controls. J Clin Pharmacol. 2025 Feb;65(2):226-232. doi: 10.1002/jcph.6134. Epub 2024 Sep 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Onradivir	Small molecule	600 mg	Oral

Indications

No indication recorded.